Order now

Yale 2019-nCoV SalivaDirect™ ValuPanel™ Reagents are now part of our ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures target the SARS-CoV-2 virus that causes COVID-19. For Research Use Only. Not for use in diagnostic procedures.

Key benefits

  • Fast delivery: Product in stock ships same or next business day
  • Gold standard quencher: From the trusted inventor and original source of Black Hole Quencher™ (BHQ™) technology referenced in 7 of 8 WHO protocols
  • Quality manufacture: All probes and primers are HPLC purified and are manufactured and shipped from a facility entirely separate from positive control production.

order now in the
new transaction portal

Item Sequence
2019-nCoV_N1 Probe FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1
2019-nCoV_N1 Forward Primer GAC CCC AAA ATC AGC GAA AT
2019-nCoV_N1 Reverse Primer TCT GGT TAC TGC CAG TTG AAT CTG
Human RNase P Probe SalivaDirect Quasar 670-TTC TGA CCT GAA GGC TCT GCG CG-BHQ2
Human RNase P Extraction Control Forward Primer AGA TTT GGA CCT GCG AGC G
Human RNase P Extraction Control Reverse Primer GAG CGG CTG TCT CCA CAA GT

Product info

The Yale 2019-nCoV SalivaDirect™ ValuPanel Reagents™ include FAM-BHQ and Quasar™ 670-BHQ probes and primers delivered in individual tubes in dried format. The oligonucleotide sequences were designed by US Centers for Disease Control and Prevention for use in real-time RT-PCR to detect SARS-CoV-2 viral strains.

The panel contains probes and primers comprising the following genetic signatures:

  • SARS-CoV-2 N1 Primers (Forward and Reverse)
  • SARS-CoV-2 N1 Probe
  • Human RNase P Primers (Forward and Reverse)
  • Human RNase P Probe (Quasar 670, SalivaDirect specific)

SalivaDirect is a protocol, developed by the Yale School of Public Health, for testing people suspected of SARS-CoV-2 infection. While the method still relies on RT-qPCR, it uses saliva samples instead of nasopharyngeal swabs. SalivaDirect was issued an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) on August 15, 2020.

Learn more about SalivaDirect and how to apply to become a SalivaDirect-authorized lab. You can also view the full protocol on Protocols.io.

Each reaction requires the following:

  • N1 forward and reverse primers: 400 nM/reaction
  • N1 probe: 200 nM/reaction
  • RNase P forward and reverse primers: 150 nM/reaction
  • RNase P probe: 200 nM/reaction

order now in the
new transaction portal

Resources

Recommended products

PCR reagents* including master mix and enzyme for SARS-CoV-2 assay development are also available

Item name  
sbeadex viral RNA purification kit View product
RapiDxFire 1-step RT-qPCR System View product

For a complete SARS-CoV-2 Quality Solution, consider the AccuPlex™ SARS-CoV-2 Verification Panel coupled with the AccuPlex™ SARS-CoV-2 Reference Material Kit from LGC SeraCare Life Sciences. The target sequence of interest is packaged into a stable non-infectious, and replication-deficient alphavirus particle and the products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Also includes negative materials targeting the human RNase P gene.

What do you require to develop your SARS-CoV-2 assay?

We offer probes and primers specific to Coronavirus as well as enzymes, master mix, and extraction capabilities.

Let’s discuss your needs

Related products

Item name  
2019-nCoV CDC-qualified Probe and Primer Kits for SARS-CoV-2 View product
Charité 2019-nCoV BBQ-650 ValuPanel Reagents* View product
Charité 2019-nCoV BHQ ValuPanel Reagents* View product
US CDC 2019-nCoV ValuPanel Reagents* View product

 

*For Research Use Only. Not for use in diagnostic procedures.